Dashboard
Manage Tickers

NVSNOVARTIS AG

NYSE novartis.com


$ 116.17 $ 0.47 (0.41 %)    

Wednesday, 18-Sep-2024 14:50:52 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 476.31 $ 1.75 (0.37 %)
DIA $ 418.54 $ 1.64 (0.39 %)
SPY $ 565.45 $ 1.59 (0.28 %)
TLT $ 100.13 $ -0.19 (-0.19 %)
GLD $ 238.27 $ 0.08 (0.04 %)
$ 115.7
$ 116.27
$ 116.30 x 100
-- x --
$ 115.63 - $ 116.58
$ 88.80 - $ 120.92
872,706
na
236.49B
$ 0.57
$ 15.93
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

incyte-downgraded---analyst-notes-intense-competition-particularly-in-larger-markets
Incyte Downgraded - Analyst Notes Intense ...
09/18/2024 18:44:19

Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-s...

novartis-multiple-sclerosis-drug-data-shows-most-patients-remain-with-no-disability-progression-for-up-to-six-years
Novartis' Multiple Sclerosis Drug Data Sho...
09/18/2024 16:03:25

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

novartis-announced-new-data-from-alithios-open-label-extension-study-showing-first-line-kesimpta-ofatumumab-treatment-for-up-to-six-years-led-to-less-disability-and-disease-progression-in-recently-diagnosed-and-treatment-nave-relapsing-multiple-sclerosis-patients-vs-those-who-switched-from-teriflunomide
Novartis Announced New Data From ALITHIOS ...
09/18/2024 10:02:45

the-fda-approves-novartis-kisqali-ribociclib-in-combination-with-an-aromatase-inhibitor-for-the-adjuvant-treatment-of-hormone-receptor-positivehuman-epidermal-growth-factor-receptor-2-negative-stage-ii-and-iii-early-breast-cancer-at-high-risk-of-recurrence
The FDA Approves Novartis' Kisqali (Riboci...
09/18/2024 10:01:11

fda-approves-novartis-kisqali-to-reduce-risk-of-recurrence-in-people-with-hrher2--early-breast-cancer
FDA Approves Novartis Kisqali To Reduce Ri...
09/17/2024 17:05:00

- Bloomberg

in-an-updated-analysis-from-phase-3-natalee-trial-of-novartis-kisqali-ribociclib-added-to-endocrine-therapy-shows-deepening-benefit-beyond-three-year-treatment-period-reducing-risk-of-recurrence-by-285-compared-to-et-alone-for-stage-ii-and-iii-hormone-receptor-positivehuman-epidermal-growth-factor-receptor-2-negative-early-breast-cancer
In An Updated Analysis From Phase 3 NATALE...
09/16/2024 08:33:38

this-novartis-analyst-is-no-longer-bullish-here-are-top-downgrades-for-wednesday
This Novartis Analyst Is No Longer Bullish...
09/11/2024 16:13:54

dominos-pizza-to-510-here-are-10-top-analyst-forecasts-for-wednesday
Domino's Pizza To $510? Here Are 10 Top An...
09/11/2024 13:08:03

b-of-a-securities-downgrades-novartis-to-neutral-lowers-price-target-to-130
B of A Securities Downgrades Novartis to N...
09/11/2024 10:29:36

B of A Securities analyst Graham Perry downgrades Novartis (NYSE:NVS) from Buy to Neutral and lowers the price target from $...

enliven-therapeutics-leukemia-candidate-could-challenge-pfizer-astrazeneca-in-broader-target-market-analyst
Enliven Therapeutics' Leukemia Candidate C...
09/09/2024 18:05:21

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwr...

goldman-sachs-shifts-stance-on-novartis-cites-lack-of-near-term-catalysts
Goldman Sachs Shifts Stance On Novartis, C...
09/05/2024 18:34:15

Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential.

sp-global-to-rally-around-10-here-are-10-top-analyst-forecasts-for-thursday
S&P Global To Rally Around 10%? Here Are 1...
09/05/2024 12:19:41

Core News & Articles
Voyager Therapeutics Announces Novartis Li...
09/05/2024 12:04:45

goldman-sachs-downgrades-novartis-to-neutral-raises-price-target-to-121
Goldman Sachs Downgrades Novartis to Neutr...
09/05/2024 10:49:10

Goldman Sachs analyst James Quigley downgrades Novartis (NYSE:NVS) from Buy to Neutral and raises the price target from $119...

despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs
Despite Medicare Negotiations, Americans M...
09/03/2024 19:12:09

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly hig...

jefferies-downgrades-novartis-to-hold
Jefferies Downgrades Novartis to Hold
09/03/2024 12:12:34

Jefferies analyst Peter Welford downgrades Novartis (NYSE:NVS) from Buy to Hold.

novartis-cholesterol-lowering-drug-shows-encouraging-outcome-in-late-stage-study
Novartis' Cholesterol-Lowering Drug Shows ...
08/28/2024 13:33:36

Novartis announced positive Phase 3 V-MONO study results for Leqvio, showing significant LDL-C reduction in low and moderate AS...

novartis-pharma-ag-a-subsidiary-of-novartis-inked-a-exclusive-global-licensing-agreement-and-strategic-collaboration-with-lindy-biosciences-for-multi-target-drug-delivery-innovation
Novartis Pharma AG, A Subsidiary Of Novart...
08/28/2024 11:00:01

novartis-phase-3-v-mono-study-for-twice-yearly-leqvio-inclisiran-met-its-primary-endpoints-showing-leqvio-monotherapy-lowered-low-density-lipoprotein-cholesterol-versus-placebo-and-ezetimibe-in-patients-who-were-at-low-or-moderate-risk-of-developing-atherosclerotic-cardiovascular-disease-and-not-receiving-lipid-lowering-therapy
Novartis' Phase 3 V MONO Study For Twice-y...
08/28/2024 10:13:50

siemens-healthineers-to-buy-novartis-diagnostics-to-bolster-cancer-scan-business-in-220m-deal
Siemens Healthineers To Buy Novartis Diagn...
08/26/2024 12:54:18

Siemens Healthineers to acquire Novartis' diagnostics division for over €200M, securing a vital supply of radioactive chemi...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION